Indication

Post-Traumatic Stress Disorder

104 clinical trials

94 products

3 drugs

Product
Methylone
Product
Placebo
Product
JZP150
Product
MDMA
Product
Lactose
Product
Psilocybin
Clinical trial
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Status: Active (not recruiting), Estimated PCD: 2023-12-19
Product
BI 1358894
Product
PRAX-114
Product
ALTO-100
Product
Sertraline
Clinical trial
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Status: Active (not recruiting), Estimated PCD: 2023-10-30
Product
BNC210
Product
Etomidate
Clinical trial
Optimal Treatment of Veterans With PTSD and Comorbid Opiate Use Disorder (OUD)
Status: Terminated, Estimated PCD: 2023-04-14
Clinical trial
Noradrenergic Biomarkers in PTSD: Precision Medicine & Mechanisms
Status: Recruiting, Estimated PCD: 2024-06-28
Product
Prazosin
Product
Fluoxetine
Product
Perampanel
Product
Dronabinol
Product
Reboxetine
Product
Topiramate
Product
Ketamine
Product
Midazolam
Product
BX-1
Product
CBD
Clinical trial
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
Status: Not yet recruiting, Estimated PCD: 2030-06-01
Product
Bavarostat
Clinical trial
Neurosteroid Intervention for PTSD in Iraq/Afghanistan-era Veterans
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder
Status: Withdrawn, Estimated PCD: 2025-12-01
Product
MDMA-AT
Clinical trial
Imaging the Neuroimmune System in PTSD With PET
Status: Active (not recruiting), Estimated PCD: 2023-05-30
Clinical trial
Imaging SV2A in Mood Disorders
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Wayne Warrior CAnnabis Research and Education: Cannabis and Behavioral Health
Status: Not yet recruiting, Estimated PCD: 2030-12-31
Product
Baclofen
Product
iSWAB-DNA
Clinical trial
MDMA-assisted Massed Prolonged Exposure for PTSD
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Improving Therapeutic Learning for PTSD
Status: Recruiting, Estimated PCD: 2023-12-01
Product
L-DOPA
Clinical trial
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Status: Recruiting, Estimated PCD: 2033-03-01
Clinical trial
Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults
Status: Not yet recruiting, Estimated PCD: 2024-04-30
Product
SM-001
Clinical trial
An Electrophysiological Predictor of SSRI Response in Veterans With PTSD
Status: Recruiting, Estimated PCD: 2025-03-30
Product
Placebos
Product
Oxytocin
Clinical trial
Combining Topiramate and Prolonged Exposure for PTSD and Alcohol Use Disorder
Status: Completed, Estimated PCD: 2022-10-31
Product
topiramate
Product
Ibuprofen
Product
Tramadol
Product
Morphine
Clinical trial
A Dose Optimization Study of MDMA-Assisted Therapy for PTSD in U.S. Veterans
Status: Not yet recruiting, Estimated PCD: 2029-10-01
Product
Lofexidine
Clinical trial
Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Pilot Test of Intranasal Oxytocin as an Enhancer of Brief Couples Therapy for PTSD
Status: Completed, Estimated PCD: 2022-09-30
Product
suvorexant
Clinical trial
Assisted Animal Therapy in a French Intensive Care Unit (ICU): An Open Randomized Study
Status: Terminated, Estimated PCD: 2022-08-24
Clinical trial
Silexan in the Treatment Of Posttraumatic Stress Disorder (STOP) Trial
Status: Not yet recruiting, Estimated PCD: 2027-02-28
Product
Silexan
Product
aleozen
Clinical trial
FAAH Availability in Psychiatric Disorders: A PET Study
Status: Terminated, Estimated PCD: 2021-06-30
Clinical trial
Suvorexant and Trauma Related Insomnia
Status: Completed, Estimated PCD: 2021-04-30
Product
Niacin
Clinical trial
Repurposing Low-Dose Clonidine for PTSD in Veterans
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Clonidine
Clinical trial
Neurosteroids in PTSD - Biomarkers to Therapeutics
Status: Terminated, Estimated PCD: 2020-11-16
Product
DHEA